Carotid Artery Stenting, Carotid Endarterectomy, Best Medical Treatment, Carotid Artery Stenosis Asymptomatic
Conditions
Keywords
Carotid Revascularization, Carotid Artery Stenting, Carotid Endarterectomy, Best Medical Treatment, Carotid Artery Stenosis Asymptomatic
Brief summary
This is a multicenter, open, randomized controlled trial to evaluate the efficacy and safety of carotid artery stenting/carotid endarterectomy versus best medical treatment for asymptomatic carotid artery stenosis in Chinese population.
Detailed description
This is a multicenter, open, randomized controlled trial to evaluate the efficacy and safety of carotid artery stenting/carotid endarterectomy versus best medical treatment for asymptomatic carotid artery stenosis in Chinese population. The study will be conducted at 11 centers and is expected to enroll 1056 patients.
Interventions
PROCEDURECarotid Revascularization
Carotid Artery Stenting/Carotid Endarterectomy
DRUGMedical Treatment
Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up. In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment.
Sponsors
China-Japan Friendship Hospital
First Affiliated Hospital Xi'an Jiaotong University
The First Affiliated Hospital of Zhengzhou University
Changhai Hospital
Peking Union Medical College Hospital
Hebei General Hospital
The Second Hospital of Hebei Medical University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
People's Hospital of Xinjiang Uygur Autonomous Region
Fifth Affiliated Hospital of Zhengzhou University
Xuanwu Hospital, Beijing
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age 40-80 years; 2. Carotid artery stenosis 50%-90% (ultrasound, CT, or DSA); 3. Asymptomatic carotid stenosis, that is, no transient ischemic attack, stroke, or other neurological symptoms in the past 6 months; 4. Patients who could complete 12 months of follow-up; 5. Patients who signed informed consent forms.
Exclusion criteria
1. Patients who had a TIA, stroke, or other related neurological symptoms within the previous 6 months; 2. Patients with spontaneous intracerebral hemorrhage in the past 12 months； 3. Patients with large intracranial aneurysms (diameter\> 5mm)，and cannot be treated in advance or contemporaneous; 4. Chronic total occlusion without obvious cerebral ischemia symptoms； 5. Patients with neurologic disorder that caused transient or permanent neurological deficits and can not be identified with transient ischemic attack or stroke； 6. Patients with severe dementia; 7. Common carotid artery opening lesion； 8. Severe intracranial stenosis in tandem; 9. Carotid artery dissection; 10. Carotid artery aneurysm; 11. Myocardial infarction occurred within 30 days； 12. It is known that two or more proximal or main coronary artery stenosis ≥70%, untreated or unable to recanalize; 13. Ejection fraction \<30% or New York Heart Association (NYHA) functional class III or higher；Unstable angina，ie angina at resting state and electrocardiogram changes； 14. Patients with cardiac emboli sources, such as left ventricular aneurysm, intraluminal filling defect, cardiomyopathy, aortic or mitral prosthetic heart valve, calcific aortic stenosis, infective endocarditis, mitral stenosis, atrial septal defect, atrial septal aneurysm, or left atrial myxoma； 15. Platelet count \<5×104/μL, INR\>1.5, Bleeding time \> 1 min, or heparin-related thrombocytopenia；Patients contraindicated to heparin and antiplatelet drugs; 16. Patients with coagulation dysfunction. 17. Poor control of diabetes, fasting blood glucose \>22mmol/L and ketone body \> +2； 18. Malignant tumor or respiratory insufficiency, life expectancy \< 5 years. 19. Insufficiency of vital organs: forced expiratory volume at one second \< 30% (predicted)； dialysis-dependent renal failure; intolerance to anesthesia; 20. Currently waiting main organ transplants (ie heart, lung, liver, kidney), or are doing relevant evaluate； 21. Need to perform other general anesthesia surgery during the same period； 22. Pregnant or lactating women； 23. Those who participated in clinical trials of other drugs or medical devices before the inclusion did not reach the end of the time limit； 24. Investigators consider the patient inappropriate to participate in this clinical trial；
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Any Periprocedural Stroke, Myocardial Infarction, or Death During1 month Peri-procedural Period, and Postprocedural Ipsilateral Stroke 1 to 12-months. | 0 to 12 months | Composite of any periprocedural stroke (ipsilateral or contralateral; major or minor), myocardial infarction, or death during1 month peri-procedural period, and postprocedural ipsilateral stroke 1 to 12-months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of complications | 30 days | Rate of complications within 30 days, complications include：Cranial nerve and peripheral nerve injury, vascular injury, non cerebral hemorrhage, wound complications as neck incision or related to puncture site, and other (such as anesthesia) complications. |
| Incidence of myocardial infarction | 30 days | Incidence of myocardial infarction at 30 days follow up. |
| Incidence of ipsilateral stroke | 30 days | Incidence of ipsilateral stroke at 30 days follow up. |
| Technical success rate | 1 day | Technical success was defined as final residual stenosis less than 30%, TIMI grade 3, and no dissection or thrombus after any endovascular treatment. |
| Carotid restenosis rate | 12 months | Carotid restenosis was defined as restenosis ≥50% after carotid revascularization, that is, peak systolic velocity ratio (PSVR) ≥2.0 on ultrasound examination. |
| Incidence of target lesion revascularization | 12 months | Target lesion revascularization (TLR) is defined as the re-percutaneous intervention or bypass grafting of the target lesion for restenosis or other complications of the target lesion. All TLR should be preclassified as clinically drived or non-clinically drived before the investigator performs angiography again. |
| Improvement in cognitive function | 30 days | Cognitive function was assessed by Montreal Cognitive Assessment Scale (MoCA) at 30 days follow up. |
| Incidence of death | 30 days | Incidence of death at 30 days follow up. |
Countries
China
Contacts
Primary ContactYongquan Gu, Dr.
Backup ContactXixiang Gao, Dr.
Outcome results
None listed